. 2003 Sep;18(9):755–763. doi: 10.1046/j.1525-1497.2003.20833.x

Table 2.

Characteristics of Studies Included in Endoscopy-negative Group

		Participants		Intervention
First Author, Year Published	Design	N	Inclusion Criteria	PPI Arm	PPI Arm	H₂RA Arm	Placebo Arm	Duration, Wk
Armstrong, 2001⁴¹	R, DB	78	Significant heartburn for at least 6 mo, at least 4 episodes/wk	Pan 40 mg/d	—	Niz 150 mg bid	—	4
Bate, 1996⁵²	R, DB	209	Heartburn predominant, overall symptoms moderate	Ome 20 mg/d	—	—	Placebo	4
Bate, 1997⁴²	R, DB	103	Heartburn predominant last mo, on at least 2 d last wk	Ome 20 mg/d	—	Cim 400 mg qid	—	4
Carlsson, 1998⁴⁷	R, DB	261	Heartburn for at least 3 mo, symptoms on at least 2 d last wk	Ome 20 mg/d	Ome 10 mg/d	—	Placebo	4
Lind, 1997⁴⁹,⁵⁰	R, DB	509	Heartburn predominant past y on at least 2 d weekly	Ome 20 mg/d	Ome 10 mg/d	—	Placebo	4
Miner, 2002⁵³	R, DB	199	Heartburn for at least 3 mo	Rab 20 mg/d	Rab 10 mg/d	—	Placebo	4
Richter, 2000⁵⁴	R, DB	359	At least 1 y with heartburn as predominant symptom of GERD, and moderate to severe on at least 4 d last wk	Ome 20 mg/d	Ome 10 mg/d	—	Placebo	4
Riemann, 1991⁴⁸	R, DB	125	Heartburn and regurgitation for at least 2 mo, on at least 5 d last wk	—	—	Cim 200 mg qid	Placebo	2
Venables, 1997⁴³	R, DB	677	Heartburn predominant for at least 3 mo, on at least 2 d last wk	Ome 20 mg/d	Ome 10 mg/d	—	—	4

R, randomized; DB, double-blinded; pan, pantoprazole; ome, omeprazole; rab, rabeprazole; niz, nizatidine; cim, cimetidine; bid, twice daily; qid, four times daily.